2076975 2077203
최종편집 2024-03-29 10:12 (금)
Pfizer’s retained earnings exceeded KRW 300 billion, surpassing Otsuka
상태바
Pfizer’s retained earnings exceeded KRW 300 billion, surpassing Otsuka
  • Hyeokgi Lee, Newsmp
  • 승인 2022.04.26 14:29
  • 댓글 0
이 기사를 공유합니다

Pfizer Pharmaceutical Korea leads among multinational pharmaceutical companies’ subsidiaries in Korea… Otsuka, KRW 249 billion
AstraZeneca KRW 172.8 billionㆍJanssen KRW 141.9 billionㆍRoche KRW 135 billion

[Newsmp] Pfizer Pharmaceutical Korea’s retained earnings have soared by more than KRW 90 billion over the past year to KRW 300 billion.

Newsmp tallied the income statements of multinational companies’ subsidiaries in Korea, whose closing accounts are between September and December, and found that of the 34 companies, 27 have increased their retained earnings or decreased their deficits.

On the other hand, retained earnings of seven companies decreased or deficits increased from 2020.

Including Organon, which was newly added last year, the combined retained earnings of 35 companies amounted to KRW 1.6267 trillion, up KRW 278.1 billion, or 20.6% from 2020.

By company, Pfizer’s retained earnings increased by KRW 95.9 billion in a year, MSD by KRW 60.9 billion, and Janssen by KRW 38.1 billion.

The retained earnings of nine companies, including GSK, AstraZeneca, Otsuka, Viatris, Novartis, and Novo Nordisk, rose by more than KRW 10 billion.

On the contrary, the loss of Janssen Vaccine grew by KRW 29.6 billion and MundiPharma by KRW 11.5 billion, during the same period.

Galderma, which reported a loss of KRW 1.8 billion in 2020, left retained earnings of KRW 100 million, and Amgen revealed a loss of KRW 100 million from KRW 7.5 billion of retained earnings.

As of the end of 2021, Pfizer took the lead with KRW 306.2 billion, surpassing KRW 300 billion, followed by Otsuka, who took first place last year, with KRW 249 billion.

Moreover, AstraZeneca had retained earnings of KRW 172.8 billion, Janssen of KRW 141.9 billion, and Roche of KRW 135 billion.

MSD and GSK rose to the KRW 90 billion mark, followed by Novartis with KRW 80 billion, Sanofi-Aventis with KRW 70 billion, and Lilly and Bayer with KRW 60 billion.

Viatris recorded the KRW 40 billion mark, followed by Kyowa Kirin, BMS, Alcon, Boehringer Ingelheim, and Novo Nordisk at KRW 300 billion, AbbVie, Fresenius Kabi, and Sanofi Pasteur at KRW 20 billion, Allergan, Servier, UCB, Ferring, and GSK Consumer Healthcare at KRW 10 billion, and Celgene, Lundbeck, Organon, Biogen, and Galderma fell below the KRW 10 billion mark.

In the meantime, the deficit of Mundipharma increased to KRW 143.6 billion, and Menarini also maintained a loss of KRW 64.9 billion.

Janssen Vaccine also saw its deficit increase significantly from KRW 5.4 billion to KRW 35 billion, and Guerbet could not clear the deficit.


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.